The European University of Madrid(UEM) and the Spanish Association of Orphan and Ultra Orphan Drug Laboratories (AELMHU) have signed a collaboration agreement to carry out joint training, teaching, counseling and research activities.
The agreement was signed during a visit to the UEM campus, located in Villaviciosa de Odón (Madrid), during which the Vice-Dean of the Degree in Pharmacy, Dr. Ana María Fernández Olleros, and Elena Pérez Izquierdo, Professor of Pharmaceutical Technology and Director of the Master's Degree in Drug Discovery, visited with the President and Executive Director of AELMHU, Beatriz Perales and Marian Corral, respectively, to see the facilities of the university center.
The agreement includes the possibility of joint organization by both entities of training activities, such as courses, congresses, seminars, etc., as well as studies and research projects, mutual advice and exchange of information and documentation.
"From the European University of Madrid, we celebrate this strategic alliance with AELMHU, which will allow us to strengthen our commitment to specialized training, applied research and knowledge transfer in an area of great social impact such as orphan and ultra-orphan drugs. This collaboration represents a unique opportunity for our students and faculty to actively participate in projects that respond to the real needs of patients with rare diseases. In addition, this agreement reinforces our educational mission focused on developing professionals with a strong ethical and social conscience, capable of understanding the human dimension of disease and the value of equitable access to therapeutic innovation. Involving students in initiatives with a high social impact contributes to training not only highly qualified scientists and healthcare professionals, but also citizens committed to the collective welfare. We are convinced that the union between academia and the pharmaceutical sector is key to promoting innovative solutions, improving access to treatments and moving towards more inclusive, sustainable and patient-centered healthcare," said the director of the Official Master's Degree in Drug Discovery.
"The collaboration with an academic institution of reference such as the European University of Madrid will allow us to advance in a key area, such as training and research on orphan and ultra-orphan drugs. It will also help to bring scientific knowledge and innovation closer to future healthcare professionals, generating a real impact on the improvement of care for patients with rare diseases. We believe that this agreement is an important step to continue joining efforts between academia and the pharmaceutical sector, always for the benefit of patients," said the president of AELMHU.
With this agreement, both institutions reaffirm their commitment to work in a coordinated manner to promote innovation, research and quality training, contributing to the development of a more equitable healthcare system focused on the needs of people with rare diseases.
